Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Deutsche Boerse AG  >  GlaxoSmithKline    GS7   GB0009252882

GLAXOSMITHKLINE

(GS7)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

GlaxoSmithKline Submits New Application for Synflorix in EU

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/17/2012 | 05:57am EDT

LONDON--GlaxoSmithKline PLC (>> GlaxoSmithKline plc), a research-based pharmaceutical and healthcare company, said Monday it has submitted a regulatory application in the European Union, or E.U., seeking approval of an additional indication for Synflorix(>> TOYOTA MOTOR CORPORATION), a paediatric pneumococcal vaccine, for the active immunization against pneumonia caused by Streptococcus pneumoniae in infants and children from six weeks up to five years of age.

MAIN FACTS:

- Application was submitted as a variation to the Marketing Authorization Application to the European Medicines Agency.

-Synflorix is currently approved in the E.U. and 90 other countries for active immunization against invasive disease and acute otitis media caused by Streptococcus pneumoniae in infants and children from six weeks up to five years of age.

-Of these 90 countries, 67 already have the indication for pneumonia approved.

-Synflorix isn't approved for use in the U.S.

-Shares at 0935 GMT up 7 pence, or 0.49%, at 1424 pence valuing the company at 70.3 million pounds

-Write to Ian Walker at ian.walker@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : GlaxoSmithKline plc, TOYOTA MOTOR CORPORATION
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE 0.59% 18.09 Delayed Quote.8.78%
GLAXOSMITHKLINE 0.70% 1657.2 Delayed Quote.11.19%
TOYOTA MOTOR CORP -0.07% 6790 End-of-day quote.9.87%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
08/14Germany's Stada 'very selective' on acquisitions - CEO Goldschmidt
RE
08/08Merck KGaA's profit bolstered by lab supplies, drug milestone payments
RE
08/08GLAXOSMITHKLINE : Ex-dividend day for interim dividend
FA
08/06GSK ends development of Ebola vaccine, hands work to U.S. institute
RE
08/05IBM and other companies launch new blockchain network for supply management
RE
08/01GLAXOSMITHKLINE : Asthma Treatment Gets Green Light From EC for Self Administeri..
DJ
08/01GLAXOSMITHKLINE : EU approval for Nucala self-administration
PU
07/31ViiV Healthcare - Five years on, 3.9 million people in the developing world h..
AQ
07/31GLAXOSMITHKLINE : ViiV Healthcare group - Five years on, 3.9 million people in t..
AQ
07/30GLAXOSMITHKLINE : ViiV Healthcare submits regulatory application to European Med..
AQ
More news
Financials (GBP)
Sales 2019 32 444 M
EBIT 2019 8 760 M
Net income 2019 4 631 M
Debt 2019 22 986 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 -
EV / Sales2019 3,02x
EV / Sales2020 2,82x
Capitalization 74 891 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 1 652,05  GBp
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Paul Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE8.78%98 651
JOHNSON & JOHNSON1.15%344 517
ROCHE HOLDING LTD.12.24%235 575
ROCHE HOLDING13.20%235 575
MERCK AND COMPANY11.32%213 689
NOVARTIS17.81%202 958